Published in Inflamm Res on June 07, 2012
Scavenger receptor class A member 3 (SCARA3) in disease progression and therapy resistance in multiple myeloma. Leuk Res (2013) 0.83
Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma. Redox Biol (2014) 0.81
Drug metabolism and clearance system in tumor cells of patients with multiple myeloma. Oncotarget (2015) 0.80
Oxidative stress and proteasome inhibitors in multiple myeloma. Pharmacol Res (2016) 0.77
The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol (2004) 5.14
Protein S-nitrosylation in health and disease: a current perspective. Trends Mol Med (2009) 3.75
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood (2006) 2.91
S-nitrosylation from GSNOR deficiency impairs DNA repair and promotes hepatocarcinogenesis. Sci Transl Med (2010) 2.13
Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem (2008) 1.97
Study of antioxidant levels in patients with multiple myeloma. Leuk Lymphoma (2009) 1.69
Key role of Src kinase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cells. J Biol Chem (2006) 1.52
The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood (2007) 1.33
Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway. Antioxid Redox Signal (2008) 1.27
AGE-RAGE system and carcinogenesis. Curr Pharm Des (2008) 1.24
AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int (2004) 1.19
Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis. Carcinogenesis (2009) 1.17
Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH. Blood (2011) 1.15
Role of oxidative/nitrosative stress-mediated Bcl-2 regulation in apoptosis and malignant transformation. Ann N Y Acad Sci (2010) 1.11
Role of advanced glycation end products (AGEs) in osteoporosis in diabetes. Curr Drug Targets (2011) 1.11
In situ accumulation of advanced glycation endproducts (AGEs) in bone matrix and its correlation with osteoclastic bone resorption. Bone (2011) 1.04
Oxidant/antioxidant parameters and their relationship with medical treatment in multiple myeloma. Cell Biochem Funct (2004) 0.97
Autophagy counteracts apoptosis in human multiple myeloma cells exposed to oridonin in vitro via regulating intracellular ROS and SIRT1. Acta Pharmacol Sin (2011) 0.96
Cancer malignancy is enhanced by glyceraldehyde-derived advanced glycation end-products. J Oncol (2010) 0.96
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 0.91
BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma. Br J Cancer (2010) 0.91
Advanced glycation end products affect growth and function of osteoblasts. Clin Exp Rheumatol (2011) 0.90
Interleukin-6 counteracts therapy-induced cellular oxidative stress in multiple myeloma by up-regulating manganese superoxide dismutase. Biochem J (2012) 0.87
Lipid peroxidation and protein oxidation in patients affected by Hodgkin's lymphoma. Mediators Inflamm (2004) 0.85
RAGE and its ligands in bone metabolism. Front Biosci (Schol Ed) (2011) 0.83
Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med (2012) 5.87
Mechanisms of antibacterial action of three monoterpenes. Antimicrob Agents Chemother (2005) 1.92
Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol (2012) 1.81
Increased serum levels of neutrophil gelatinase-associated lipocalin in patients with essential thrombocythemia and polycythemia vera. Leuk Lymphoma (2010) 1.46
The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience. Am J Hematol (2011) 1.27
Cadmium concentration in maternal and cord blood and infant birth weight: a study on healthy non-smoking women. J Perinat Med (2002) 1.02
Clinical and laboratory features of 103 patients from 42 Italian families with inherited thrombocytopenia derived from the monoallelic Ala156Val mutation of GPIbα (Bolzano mutation). Haematologica (2011) 1.02
High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications. Br J Haematol (2014) 1.00
Antioxidant properties of 4-methylcoumarins in in vitro cell-free systems. Biochimie (2010) 0.98
Concentration of circulating endothelial progenitor cells (EPC) in normal pregnancy and in pregnant women with diabetes and hypertension. Am J Obstet Gynecol (2007) 0.98
A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. Br J Haematol (2013) 0.97
Biomolecular characterization of wild sicilian oregano: phytochemical screening of essential oils and extracts, and evaluation of their antioxidant activities. Chem Biodivers (2013) 0.94
Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features. Clin Cancer Res (2013) 0.92
Differential levels of soluble endoglin (CD105) in myeloid malignancies. J Cell Physiol (2003) 0.91
Protective effects of a red orange extract on UVB-induced damage in human keratinocytes. Biofactors (2007) 0.89
Toxic effect of nickel in an in vitro model of human oral epithelium. Toxicol Lett (2005) 0.87
Anthocyanins protect human endothelial cells from mild hyperoxia damage through modulation of Nrf2 pathway. Genes Nutr (2012) 0.87
Phytocomplexes from liquorice (Glycyrrhiza glabra L.) leaves--chemical characterization and evaluation of their antioxidant, anti-genotoxic and anti-inflammatory activity. Fitoterapia (2011) 0.87
Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia. PLoS One (2011) 0.87
Levels of soluble angiogenin in chronic myeloid malignancies: clinical implications. Eur J Haematol (2004) 0.87
The cancer stem cell hypothesis: a guide to potential molecular targets. Cancer Invest (2014) 0.86
Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study. Drugs Aging (2013) 0.86
Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study. Am J Hematol (2014) 0.85
Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma. Eur J Haematol (2013) 0.85
In vitro protective effects of two extracts from bergamot peels on human endothelial cells exposed to tumor necrosis factor-alpha (TNF-alpha). J Agric Food Chem (2010) 0.85
JAK2 V617F-positive latent essential thrombocythemia and splanchnic vein thrombosis: the role of bone marrow biopsy for the diagnosis of myeloproliferative disease. Acta Haematol (2009) 0.84
Endothelial progenitor cells: pathogenetic role and therapeutic perspectives. J Nephrol (2009) 0.84
Cytotoxic effects induced in vitro by organic extracts from urban air particulate matter in human leukocytes. Drug Chem Toxicol (2013) 0.84
Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia. Am J Hematol (2012) 0.84
Virological profiles in hepatitis B virus inactive carriers: monthly evaluation in 1-year follow-up study. Liver Int (2005) 0.83
MiRNome expression is deregulated in the peripheral lymphoid compartment of multiple myeloma. Br J Haematol (2014) 0.83
Increased protein carbonyl groups in the serum of patients affected by thalassemia major. Ann Hematol (2006) 0.83
Imatinib mesylate therapy induces reduction in neutrophil gelatinase-associated lipocalin serum levels and increase in leptin concentrations in chronic myeloid leukemia patients in molecular remission. Acta Haematol (2011) 0.83
Influence of glutathione S-transferases polymorphisms on biological monitoring of exposure to low doses of benzene. Toxicol Lett (2011) 0.82
Bisphosphonates induce apoptosis of circulating endothelial cells in multiple myeloma patients and in subjects with bisphosphonate-induced osteonecrosis of the jaws. Acta Haematol (2010) 0.82
Oxidative stress in oncohematologic diseases: an update. Expert Rev Hematol (2013) 0.82
In vitro antioxidant and in vivo photoprotective effect of pistachio (Pistacia vera L., variety Bronte) seed and skin extracts. Fitoterapia (2013) 0.82
Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors. Eur J Haematol (2010) 0.82
Possible role of erythropoietin in the pathogenesis of chronic cor pulmonale. Nephrol Dial Transplant (2005) 0.82
Reduced serum levels of Interleukin 17 in patients with osteonecrosis of the jaw and in multiple myeloma subjects after bisphosphonates administration. Cytokine (2008) 0.81
Serum interleukin-23 (IL-23) is increased in Hashimoto's thyroiditis. Endocr J (2014) 0.80
Heavy metals in liver and muscle of bluefin tunA (Thunnus thynnus) caught in the Straits of Messina (Sicily, Italy). Environ Monit Assess (2005) 0.80
Serum levels of protein oxidation products in patients with nickel allergy. Allergy Asthma Proc (2009) 0.80
Reduced IL-33 plasma levels in multiple myeloma patients are associated with more advanced stage of disease. Br J Haematol (2012) 0.80
Decreased plasma levels of IL-33 could contribute to the altered function of Th2 lymphocytes in patients with polycythemia vera and essential thrombocythemia. Cancer Invest (2013) 0.80
Epigenetic therapy in myelodysplastic syndromes. Eur J Haematol (2010) 0.80
Familial B-cell chronic lymphocytic leukemia in a population of patients from Southern Italy. Int J Hematol (2004) 0.79
Cardiac involvement in patients with hematologic malignancies. J Investig Med (2010) 0.79